-

10:08:36 PM

SRPT Stock News

SRPT - Sarepta Therapeutics Inc

10/13/21 9:15 PM

Nasdaq : SRPT

offering

Sarepta Therapeutics Announces Pricing of $500 Million Public Offering of Common Stock

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has priced an underwritten public offering of 6,172,840 shares of its common stock at a price to the public of $81.00

RHEA-AI

neutral

10/12/21 4:04 PM

Nasdaq : SRPT

earnings

Sarepta Therapeutics Announces Preliminary Financial Results for the Third Quar-ter Ended September 30, 2021

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced preliminary financial results for its third quarter ended September 30, 2021. Sarepta expects its net product revenues for the

RHEA-AI

neutral

10/12/21 4:01 PM

Nasdaq : SRPT

offering

Sarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock

Sarepta Therapeutics, Inc. (Nasdaq:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it is offering to sell, subject to market and other conditions, $500,000,000 in shares of its common stock in an

RHEA-AI

neutral

10/11/21 9:13 AM

Nasdaq : SRPT

Sarepta Therapeutics’ SRP-9001 Shows Sustained Functional Improvements in Multiple Studies of Patients with Duchenne

Results presented at ‘Micro-dystrophin Day’ highlight breadth, depth and strength of the clinical evidence to date for SRP-9001 in treating Duchenne muscular dystrophy; tolerability profile remains consistent across treated patients Results from Study SRP-9001-101 found that SRP-9001-treated

RHEA-AI

neutral

10/04/21 4:30 PM

Nasdaq : SRPT

Sarepta Therapeutics Opens Genetic Therapies Center of Excellence in Columbus, Ohio

Sarepta Therapeutics, Inc.

RHEA-AI

very positive

10/04/21 7:00 AM

Nasdaq : SRPT

Sarepta Therapeutics Announces Initiation of EMBARK, a Global Pivotal Study of SRP-9001, a Gene Therapy for the Treatment of Duchenne Muscular Dystrophy

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the initiation, in

RHEA-AI

neutral

09/30/21 7:06 PM

Nasdaq : SRPT

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on September 30, 2021 that were previously approved by the Compensation Committee of its Board of Directors under

RHEA-AI

very positive

09/27/21 8:30 AM

Nasdaq : SRPT

Sarepta Therapeutics to Initiate Part B of MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions with FDA

- Company Anticipates Part B of MOMENTUM to Serve as Pivotal Study for SRP-5051 and to Seek Accelerated Approval if Successful - Ambulatory and Non-Ambulatory Patients Between the Ages of 7 to 21 Will Be Eligible to Enroll in Part B of MOMENTUM CAMBRIDGE, Mass., Sept. 27, 2021

RHEA-AI

neutral

09/14/21 8:30 AM

Nasdaq : SRPT

Sarepta Therapeutics to Showcase Data from its Gene Therapy and RNA Platforms at World Muscle Society 2021 Virtual Congress

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the World Muscle Society 2021 Virtual Congress (WMS 2021), taking place Sept. 20-24, 2021. This year’s presentations at WMS

RHEA-AI

neutral

09/07/21 4:30 PM

Nasdaq : SRPT

conferences

Sarepta Therapeutics to Present at Upcoming Investor Conferences

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in fireside chats at two upcoming virtual investor conferences: Morgan Stanley Global

RHEA-AI

neutral

1 2 3 4 5 6 7 8 Next

SRPT Data:

IndustryPharmaceutical Preparation Manufacturing
Websitewww.sareptatherapeutics.com
CeoDouglas Ingram
Security nameSarepta Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees866
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address215 1st St Ste 415
StateMassachusetts
CityCambridge
Zip02142-1213
CountryUS
Phone16172744000

SRPT Description:

Sarepta Therapeutics Inc. is leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with raredisease. The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with more than 40 programs in various stages of development. The Company's programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing.